Article
Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
Cancer research - 15 Jan 2002
Hawk Natalyn, Sun Tong, Xie Shanhai, Wang Yan, Wu Yun, Liu Jiaxin, Arlinghaus Ralph B
Abstract excerpt
The BCR protein is involved in the inhibition of oncogenic activity of the Bcr-Abl oncoprotein. This inhibition is believed to be the result of binding to the SH2 domain of Bcr-Abl in a non-phosphotyrosine-dependent manner. We showed that the Arg to Leu mutation in the Phe-Leu-Val-Arg-Glu-Ser (FLVRES) sequence of the SH2 domain, known to interfere with phosphotyrosine sequence binding, did not block the binding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.